AR061341A1 - Compuesto de 5-amino-n-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)-fuorofenil]-1h-pirazol-4-carboxanmida, su uso para la preparacion de un medicamento composicion farmaceutica que lo comprende, proceso y compuestos intermediarios para su preparacion - Google Patents
Compuesto de 5-amino-n-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)-fuorofenil]-1h-pirazol-4-carboxanmida, su uso para la preparacion de un medicamento composicion farmaceutica que lo comprende, proceso y compuestos intermediarios para su preparacionInfo
- Publication number
- AR061341A1 AR061341A1 ARP070102547A ARP070102547A AR061341A1 AR 061341 A1 AR061341 A1 AR 061341A1 AR P070102547 A ARP070102547 A AR P070102547A AR P070102547 A ARP070102547 A AR P070102547A AR 061341 A1 AR061341 A1 AR 061341A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- preparation
- trifluoro
- phenyl
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto de 5-amino-N-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)- fluorofenil]-1H-pirazol-4-carboxamida, de formula (1) en la que R1 se selecciona entre hidrogeno, metilo, etilo y 2-fluoroetilo; cada uno de R2 y R3 se selecciona independientemente entre bromo, cloro, fluor, -CHF2, -CF3 y -OCHF2, o R2 es -SO2CH3 y R3 es hidrogeno; n es un numero entero seleccionado entre 0, 1 y 2, cuando n es 1, X se selecciona entre cloro y fluor, y cuando n es 2, cada X es fluor; o una sal o solvato del mismo. Uso de dicho compuesto para la preparacion de un medicamento util particularmente para el tratamiento de inflamacion, alergia y/o afecciones autoinmunes. Composicion farmacéutica que lo comprende. Proceso y compuestos intermediarios para su preparacion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0611587.7A GB0611587D0 (en) | 2006-06-12 | 2006-06-12 | Novel compounds |
| GB0625457A GB0625457D0 (en) | 2006-12-20 | 2006-12-20 | Novel compounds |
| GB0710217A GB0710217D0 (en) | 2007-05-29 | 2007-05-29 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061341A1 true AR061341A1 (es) | 2008-08-20 |
Family
ID=38659745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102547A AR061341A1 (es) | 2006-06-12 | 2007-06-11 | Compuesto de 5-amino-n-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)-fuorofenil]-1h-pirazol-4-carboxanmida, su uso para la preparacion de un medicamento composicion farmaceutica que lo comprende, proceso y compuestos intermediarios para su preparacion |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8247377B2 (es) |
| EP (1) | EP2029549B1 (es) |
| JP (1) | JP5497433B2 (es) |
| KR (1) | KR101411276B1 (es) |
| CN (1) | CN101501003B (es) |
| AR (1) | AR061341A1 (es) |
| AT (1) | ATE487703T1 (es) |
| AU (1) | AU2007260067B2 (es) |
| BR (1) | BRPI0713755A8 (es) |
| CA (1) | CA2659564C (es) |
| CR (1) | CR10489A (es) |
| CY (1) | CY1111454T1 (es) |
| DE (1) | DE602007010456D1 (es) |
| DK (1) | DK2029549T3 (es) |
| EA (1) | EA015540B1 (es) |
| ES (1) | ES2355165T3 (es) |
| GB (1) | GB0611587D0 (es) |
| HK (1) | HK1127609A1 (es) |
| HR (1) | HRP20110097T1 (es) |
| IL (1) | IL195492A0 (es) |
| MA (1) | MA30514B1 (es) |
| MX (1) | MX2008015977A (es) |
| NO (1) | NO20085100L (es) |
| PL (1) | PL2029549T3 (es) |
| PT (1) | PT2029549E (es) |
| SI (1) | SI2029549T1 (es) |
| TW (1) | TW200815360A (es) |
| WO (1) | WO2007144327A2 (es) |
| ZA (1) | ZA200810161B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0611587D0 (en) * | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| WO2010068311A1 (en) | 2008-05-23 | 2010-06-17 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein inhibitor |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| RU2632908C2 (ru) | 2011-08-18 | 2017-10-11 | Ниппон Синяку Ко., Лтд. | Гетероциклическое производное и фармацевтическое средство |
| WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| CN103468812B (zh) * | 2013-09-17 | 2015-02-25 | 安徽医科大学 | 一种检测糖皮质激素治疗sle疗效的试剂盒 |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| EP3142694A2 (en) | 2014-05-12 | 2017-03-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions comprising danirixin for treating infectious diseases |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| US10221142B2 (en) | 2015-02-11 | 2019-03-05 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
| CN104774950B (zh) * | 2015-04-21 | 2017-10-03 | 安徽医科大学 | 一种基于hsp90aa1基因型预测糖皮质激素治疗sle疗效的试剂盒 |
| JP2018531958A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用 |
| JP2018535958A (ja) | 2015-10-27 | 2018-12-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用 |
| EP3368516B1 (en) | 2015-10-27 | 2020-07-15 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| CN110452203B (zh) * | 2019-08-29 | 2021-04-13 | 忻州师范学院 | 一种1-氧代-1,3-二氢-3-羟基苯并呋喃-5-甲酸的制备方法 |
| EP4125919A1 (en) | 2020-03-26 | 2023-02-08 | GlaxoSmithKline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
| AU2023232562A1 (en) | 2022-03-08 | 2024-09-05 | Equashield Medical Ltd | Fluid transfer station in a robotic pharmaceutical preparation system |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB607839A (en) | 1946-02-12 | 1948-09-06 | Bristol Aeroplane Co Ltd | Improvements in or relating to gas-turbine power-plants |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| US5552438A (en) | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| ES2122261T3 (es) | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester. |
| RU2162841C2 (ru) | 1994-06-15 | 2001-02-10 | Де Вэллкам Фаундейшн Лимитед | Производное амидиносульфона, способ его получения (варианты), способ селективного ингибирования изофермента no синтазы, фармацевтический препарат и способ лечения |
| AP791A (en) | 1995-04-14 | 1999-12-17 | Glaxo Wellcome Inc | Metered dose inhaler for albuterol. |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| AU3328499A (en) | 1998-03-14 | 1999-10-11 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone pde iii/iv inhibitors |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| DE19856475A1 (de) * | 1998-11-27 | 2000-05-31 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| CA2371273A1 (en) | 1999-05-04 | 2000-11-09 | Andrew Fensome | Tetracyclic progesterone receptor modulator compounds and methods |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| CZ2003353A3 (cs) | 2000-08-05 | 2003-05-14 | Glaxo Group Limited | Estery steroidních thiokyselin |
| ES2527688T3 (es) | 2000-09-29 | 2015-01-28 | Glaxo Group Limited | Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ES2288543T3 (es) | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
| JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
| AR033290A1 (es) | 2001-04-30 | 2003-12-10 | Glaxo Group Ltd | Derivados antiinflamatorios de androstano |
| ES2307751T3 (es) | 2001-06-12 | 2008-12-01 | Glaxo Group Limited | Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano. |
| US7361787B2 (en) | 2001-09-14 | 2008-04-22 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
| WO2003037352A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| ATE346058T1 (de) | 2002-01-14 | 2006-12-15 | Boehringer Ingelheim Pharma | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon |
| JP4745609B2 (ja) | 2002-01-22 | 2011-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用 |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| DE60318188T2 (de) | 2002-03-26 | 2008-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung |
| JP2005521717A (ja) | 2002-03-26 | 2005-07-21 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用 |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| CA2481320A1 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| PT1521733E (pt) | 2002-07-08 | 2014-10-29 | Pfizer Prod Inc | Moduladores do recetor de glucocorticoides |
| AU2003251970A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| WO2004018429A2 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| KR20050052501A (ko) | 2002-09-16 | 2005-06-02 | 글락소 그룹 리미티드 | 피라졸로[3,4-ｂ]피리딘 화합물, 및 포스포디에스테라아제억제제로서의 이들의 용도 |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
| ES2302956T3 (es) | 2002-10-28 | 2008-08-01 | Glaxo Group Limited | Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias. |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| WO2004071389A2 (en) | 2003-02-15 | 2004-08-26 | Glaxo Group Limited | Non-steroidal infalmmation inhibitors |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| UY28526A1 (es) | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
| NZ546312A (en) | 2003-10-14 | 2008-09-26 | Glaxo Group Ltd | Muscarinic acetycholine receptor antagonists |
| CN102028994B (zh) | 2003-11-03 | 2013-04-24 | 葛兰素集团有限公司 | 流体分配装置 |
| TW200524577A (en) | 2003-11-04 | 2005-08-01 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| AR050902A1 (es) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| BRPI0518222A (pt) | 2004-10-19 | 2008-11-04 | Hoffmann La Roche | composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos |
| US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| EP1841780B1 (en) | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| US8093281B2 (en) * | 2005-04-14 | 2012-01-10 | Glaxo Group Limited | Indazoles as glucocorticoid receptor ligands |
| GB0513297D0 (en) * | 2005-06-29 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| GB0611587D0 (en) * | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| WO2008000777A2 (en) * | 2006-06-29 | 2008-01-03 | Glaxo Group Limited | Phenyl- pyrazole derivatives, process for their preparation and their pharmaceutical use |
-
2006
- 2006-06-12 GB GBGB0611587.7A patent/GB0611587D0/en not_active Ceased
-
2007
- 2007-06-11 PT PT07765362T patent/PT2029549E/pt unknown
- 2007-06-11 DE DE602007010456T patent/DE602007010456D1/de active Active
- 2007-06-11 MX MX2008015977A patent/MX2008015977A/es active IP Right Grant
- 2007-06-11 EP EP07765362A patent/EP2029549B1/en active Active
- 2007-06-11 US US12/303,791 patent/US8247377B2/en active Active
- 2007-06-11 SI SI200730484T patent/SI2029549T1/sl unknown
- 2007-06-11 TW TW096121030A patent/TW200815360A/zh unknown
- 2007-06-11 DK DK07765362.4T patent/DK2029549T3/da active
- 2007-06-11 AT AT07765362T patent/ATE487703T1/de active
- 2007-06-11 BR BRPI0713755A patent/BRPI0713755A8/pt not_active Application Discontinuation
- 2007-06-11 CA CA2659564A patent/CA2659564C/en active Active
- 2007-06-11 CN CN2007800295932A patent/CN101501003B/zh active Active
- 2007-06-11 JP JP2009514772A patent/JP5497433B2/ja active Active
- 2007-06-11 AU AU2007260067A patent/AU2007260067B2/en active Active
- 2007-06-11 WO PCT/EP2007/055724 patent/WO2007144327A2/en active Application Filing
- 2007-06-11 KR KR1020097000591A patent/KR101411276B1/ko active IP Right Grant
- 2007-06-11 AR ARP070102547A patent/AR061341A1/es unknown
- 2007-06-11 PL PL07765362T patent/PL2029549T3/pl unknown
- 2007-06-11 EA EA200802322A patent/EA015540B1/ru not_active IP Right Cessation
- 2007-06-11 ES ES07765362T patent/ES2355165T3/es active Active
-
2008
- 2008-11-25 IL IL195492A patent/IL195492A0/en unknown
- 2008-11-28 ZA ZA200810161A patent/ZA200810161B/xx unknown
- 2008-12-08 NO NO20085100A patent/NO20085100L/no not_active Application Discontinuation
- 2008-12-10 CR CR10489A patent/CR10489A/es not_active Application Discontinuation
- 2008-12-12 MA MA31473A patent/MA30514B1/fr unknown
-
2009
- 2009-07-22 HK HK09106729.6A patent/HK1127609A1/xx unknown
-
2011
- 2011-02-02 CY CY20111100112T patent/CY1111454T1/el unknown
- 2011-02-08 HR HR20110097T patent/HRP20110097T1/hr unknown
-
2012
- 2012-07-13 US US13/548,573 patent/US20120277279A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061341A1 (es) | Compuesto de 5-amino-n-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)-fuorofenil]-1h-pirazol-4-carboxanmida, su uso para la preparacion de un medicamento composicion farmaceutica que lo comprende, proceso y compuestos intermediarios para su preparacion | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| UY29562A1 (es) | Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
| UY30759A1 (es) | Compuestos quimicos | |
| CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| UY31430A1 (es) | Derivados de piridina y pirazina -83 | |
| AR060536A1 (es) | Agonista del receptor de glucocorticoides y composiciones farmaceuticas | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
| HN2012001162A (es) | Triazolopiridinas | |
| AR066344A1 (es) | Compuesto de imidazol formulacion farmaceutica que lo comprende y uso del mismo para la manufactura de un medicamento | |
| UY30183A1 (es) | Derivados de quinolina | |
| CL2012000469A1 (es) | Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit. | |
| UY29370A1 (es) | Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| ECSP088638A (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
| UY29266A1 (es) | Compuestos de piridazinona | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
| GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
| UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |